Potential Role of BCL2 and BCL6 Overexpression in Circulating Tumor Cells as Molecular Biomarkers in DLBCL After R-CHOP Therapy. (PubMed, Rev Med Chil) - Oct 21, 2026 - "The presence of BCL2 and BCL6 in CTCs suggests that liquid biopsy serves as a robust, complementary tool to PET/CT for post-treatment monitoring. These findings support the utility of BCL6 as a biomarker for residual disease surveillance in DLBCL."
Biomarker • Circulating tumor cells • IO biomarker • Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • BCL2 • BCL6 • CD20 • CTCs
|
|
Adolfo Martínez Tovar; Adrián De la Cruz Rosas; Amairani Gutiérrez Nava; Anel Irais García Laguna; Carlos Martínez Murillo; Christian Omar Ramos Peñafiel; Efreen Horacio Montano Figueroa; Gilberto Israel Barranco Lampón; Irma Olarte Carrillo; Iveth Mendoza Salas; Rafael CerónMaldo Nado; Silvia Jiménez Morales
|